LABORATORY RESEARCH Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis and Circulating Tumor Cells in Prostate Cancer Scientists report that the molecular chaperone Hsp27 drives epithelial-to-mesenchymal transition (EMT) in prostate cancer while its attenuation reverses EMT and decreases cell migration, invasion and matrix metalloprotease activity. [Cancer Res] Abstract Regulation of Several Androgen-Induced Genes through the Repression of the miR-99a/let-7c/miR-125b-2 miRNA Cluster in Prostate Cancer Cells Investigators report that androgen represses the miR-99a/let7c/125b-2 cluster through androgen receptor and anti-androgen drugs block the androgen-repression of the miRNA (microRNA) cluster. [Oncogene] Abstract Activation of Protein Kinase CK2 Attenuates FOXO3a Functioning in a PML-Dependent Manner: Implications in Human Prostate Cancer The authors propose a novel signaling axis apexed by deregulated Caseine Kinase II (CK2), dismantling the association of promyelocytic leukemia (PML) and PHLPP2 (they also report PHLPP2 to be a novel interacting partner of PML inside the nucleus), ultimately leading to the inactivation and nuclear exclusion of forkhead box O3 isoform a (FOXO3a), thereby downregulating p21/p27/Bim in which degradation of PML and the concomitant stabilization of active AKT plays a cardinal part. [Cell Death Dis] Full Article A Novel Anti-Androgen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo Investigators identified a novel anti-androgen, Compound 30, and compared its efficacy to MDV3100. They found that Compound 30 inhibits AR activity in LNCaP cells, C4-2 cells, as well as MDV3100 resistant cell lines. [Mol Cancer Ther] Abstract The Impaired Viability of Prostate Cancer Cell Lines By the Recombinant Plant Kallikrein Inhibitor Scientists demonstrated that different properties of the protease inhibitor recombinant kallikrein inhibitor may be explored for investigating the androgen-independent prostate cancer cell lines PC3 and DU145. [J Biol Chem] Abstract | Full Article PPP2R2C Loss Promotes Castration-Resistant Prostate Cancer Growth and Is Associated with Increased Prostate Cancer-Specific Mortality Researchers demonstrated that loss of PPP2R2C promotes androgen ligand depletion-resistant prostate cancer growth without altering androgen receptor (AR) expression or canonical AR-regulated gene expression. [Mol Cancer Res] Abstract Parathyroid Hormone-Related Protein Regulates Integrin α6 and β4 Levels via Transcriptional and Post-Translational Pathways Parathyroid hormone-related protein (PTHrP) enhances prostate cancer (CaP) growth and metastasis in vivo. PTHrP also increases cell survival and migration, and upregulates pro-invasive integrin α6β4 expression. The authors used the human CaP cell lines C4-2 and PC-3 as model systems to study the mechanisms via which PTHrP regulates α6β4 levels. [Exp Cell Res] Abstract CLINICAL RESEARCH Extended Pelvic Lymph Node Dissection in Prostate Cancer: A 20-Year Audit in a Single Center The authors evaluated 5274 prostate cancer patients treated with radical prostatectomy and anatomically extended pelvic lymph node dissection between 1990 and 2010. Year-per-year trends of clinical and pathological characteristics were examined. [Ann Oncol] Abstract Sargramostim (GM-CSF) and Lenalidomide in Castration-Resistant Prostate Cancer (CRPC): Results from a Phase I-II Clinical Trial In an effort to further evaluate the clinical and immune activity of granulocyte-macrophage colony-stimulating factor and lenalidomide, researchers conducted a Phase I-II trial in patients with CRPC. [Urol Oncol] Abstract |